Literature DB >> 29032895

Cardiac sympathetic denervation predicts PD in at-risk individuals.

David S Goldstein1, Courtney Holmes2, Grisel J Lopez3, Tianxia Wu4, Yehonatan Sharabi5.   

Abstract

INTRODUCTION: By the time a person develops the motor manifestations of Parkinson's disease (PD), substantial loss of nigrostriatal dopamine neurons has already occurred. There is great interest in identifying biomarkers that can detect pre-clinical PD. Braak's neuropathological staging concept imputes early autonomic involvement. Here we report results from a small prospective cohort study about the utility of neuroimaging evidence of cardiac sympathetic denervation in predicting PD among individuals with multiple PD risk factors.
METHODS: Subjects provided information about family history of PD, olfactory dysfunction, dream enactment behavior, and orthostatic hypotension at a protocol-specific website. From this pool, 27 people with at least 3 risk factors confirmed underwent cardiac 18F-dopamine positron emission tomographic scanning and were followed for at least 3 years. Interventricular septal and left ventricular free wall concentrations of 18F-dopamine-derived radioactivity were measured.
RESULTS: Of the 27 subjects, 4 were diagnosed with PD within the 3-year follow-up period (Pre-Clinical PD group); 23 risk-matched (mean 3.2 risk factors) subjects remained disease-free (No-PD group). Compared to the No-PD group, the Pre-Clinical PD group had lower initial values for septal and free wall concentrations of 18F-dopamine-derived radioactivity (p = 0.0248, 0.0129). All 4 Pre-Clinical PD subjects had evidence of decreased cardiac sympathetic innervation in the interventricular septum or left ventricular free wall, in contrast with 3 of 23 (13%) No-PD subjects (p = 0.0020 by Fisher's exact test).
CONCLUSION: People with multiple PD risk factors and diagnosed with PD within 3 years have evidence of antecedent cardiac sympathetic denervation. The findings fit with Braak's staging concept. Published by Elsevier Ltd.

Entities:  

Keywords:  Biomarkers; Fluorodopamine; Parkinson's disease; Sympathetic nervous system

Mesh:

Substances:

Year:  2017        PMID: 29032895      PMCID: PMC6319357          DOI: 10.1016/j.parkreldis.2017.10.003

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  12 in total

1.  Risk tables for parkinsonism and Parkinson's disease.

Authors:  Alexis Elbaz; James H Bower; Demetrius M Maraganore; Shannon K McDonnell; Brett J Peterson; J Eric Ahlskog; Daniel J Schaid; Walter A Rocca
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

2.  Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials.

Authors:  Ronald B Postuma; Jean-Francois Gagnon; Josie-Anne Bertrand; Daphné Génier Marchand; Jacques Y Montplaisir
Journal:  Neurology       Date:  2015-02-13       Impact factor: 9.910

3.  New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes.

Authors:  Seyed-Mohammad Fereshtehnejad; Silvia Rios Romenets; Julius B M Anang; Véronique Latreille; Jean-François Gagnon; Ronald B Postuma
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

Review 4.  Dysautonomia in Parkinson disease.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

5.  Combined use of dopamine transporter imaging (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease.

Authors:  Fumihito Yoshii; Masafuchi Ryo; Yasuhiko Baba; Takashi Koide; Jun Hashimoto
Journal:  J Neurol Sci       Date:  2017-01-14       Impact factor: 3.181

6.  Cardiac sympathetic denervation preceding motor signs in Parkinson disease.

Authors:  David S Goldstein; Yehonatan Sharabi; Barbara I Karp; Oladi Bentho; Ahmed Saleem; Karel Pacak; Graeme Eisenhofer
Journal:  Clin Auton Res       Date:  2007-03-02       Impact factor: 4.435

Review 7.  Etiology and pathogenesis of Parkinson's disease.

Authors:  Anthony H Schapira; Peter Jenner
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

8.  The Severity and Pattern of Autonomic Dysfunction in Idiopathic Rapid Eye Movement Sleep Behavior Disorder.

Authors:  Hyung Lee; Yong-Won Cho; Hyun Ah Kim
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

Review 9.  Stages in the development of Parkinson's disease-related pathology.

Authors:  Heiko Braak; Estifanos Ghebremedhin; Udo Rüb; Hansjürgen Bratzke; Kelly Del Tredici
Journal:  Cell Tissue Res       Date:  2004-08-24       Impact factor: 5.249

10.  Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.

Authors:  David S Goldstein; Courtney Holmes; Oladi Bentho; Takuya Sato; Jeffrey Moak; Yehonatan Sharabi; Richard Imrich; Shielah Conant; Basil A Eldadah
Journal:  Parkinsonism Relat Disord       Date:  2008-03-05       Impact factor: 4.891

View more
  15 in total

1.  Post mortem evaluation of inflammation, oxidative stress, and PPARγ activation in a nonhuman primate model of cardiac sympathetic neurodegeneration.

Authors:  Jeanette M Metzger; Helen N Matsoff; Alexandra D Zinnen; Rachel A Fleddermann; Viktoriya Bondarenko; Heather A Simmons; Andres Mejia; Colleen F Moore; Marina E Emborg
Journal:  PLoS One       Date:  2020-01-07       Impact factor: 3.240

Review 2.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

3.  Alpha-Synuclein Deposition Within Sympathetic Noradrenergic Neurons Is Associated With Myocardial Noradrenergic Deficiency in Neurogenic Orthostatic Hypotension.

Authors:  Risa Isonaka; Avi Z Rosenberg; Patti Sullivan; Abraham Corrales; Courtney Holmes; Yehonatan Sharabi; David S Goldstein
Journal:  Hypertension       Date:  2019-04       Impact factor: 10.190

4.  Association of innervation-adjusted alpha-synuclein in arrector pili muscles with cardiac noradrenergic deficiency in autonomic synucleinopathies.

Authors:  Risa Isonaka; Christopher H Gibbons; Ningshan Wang; Roy Freeman; David S Goldstein
Journal:  Clin Auton Res       Date:  2019-10-31       Impact factor: 4.435

5.  Long-term trends in myocardial sympathetic innervation and function in synucleinopathies.

Authors:  Guillaume Lamotte; Courtney Holmes; Tianxia Wu; David S Goldstein
Journal:  Parkinsonism Relat Disord       Date:  2019-09-16       Impact factor: 4.891

6.  Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.

Authors:  David S Goldstein; Courtney Holmes; Grisel J Lopez; Tianxia Wu; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2018-02-15       Impact factor: 4.891

Review 7.  Roles of cardiac sympathetic neuroimaging in autonomic medicine.

Authors:  David S Goldstein; William P Cheshire
Journal:  Clin Auton Res       Date:  2018-07-30       Impact factor: 4.435

8.  Artificial Intelligence-Assisted Prediction of Late-Onset Cardiomyopathy Among Childhood Cancer Survivors.

Authors:  Fatma Güntürkün; Oguz Akbilgic; Robert L Davis; Gregory T Armstrong; Rebecca M Howell; John L Jefferies; Kirsten K Ness; Ibrahim Karabayir; John T Lucas; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Elsayed Z Soliman; Daniel A Mulrooney
Journal:  JCO Clin Cancer Inform       Date:  2021-04

9.  Assessment of myocardial sympathetic innervation with 18F-FDOPA-PET/CT in patients with autonomic dysfunction: feasibility study in IPD patients.

Authors:  Harish Goyal; Anshul Sharma; Chetan Patel; K K Deepak; Madhavi Tripathi; Priyanka Gupta; Rajeev Kumar; Chandra Shekhar Bal; Vinay Goyal
Journal:  J Nucl Cardiol       Date:  2021-01-10       Impact factor: 3.872

Review 10.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.